Will ICON’s Anthropic collaboration reduce clinical trial delays and protocol amendments?
ICON and Anthropic will build Claude-powered clinical trial tools inside Orbis, targeting site selection, enrolment risk and protocol design.
Features & Analysis
Medical Devices & Diagnostics
How could CyPath Lung fit into pulmonary nodule evaluation after low-dose CT screening?
bioAffinity’s CyPath Lung framework targets pulmonary nodule decisions, but adoption still depends on prospective validation and payer support.
Pharma & Biotech
AnHorn Medicines doses first participant in Phase 1 AH-008 CIPN prevention trial
AnHorn Medicines doses the first participant in a Phase 1 AH-008 study, opening a cautious clinical test of chemotherapy neuropathy prevention.
Pharma & Biotech
Why United Therapeutics’ FDA-cleared UHeart trial could redefine xenotransplantation risk
Find out how United Therapeutics’ FDA-cleared UHeart trial could reshape xenotransplantation for end-stage heart failure patients.